Global Drug Delivery Industry Report 2019: Analysis on Injection Devices - Discussion of Products, Current/Forecast Markets, Competitors, and OpportunitiesHomeMailNewsFinanceSportsEntertainmentSearchMobileMoreYahooSearchNo matching results for ''Tip: Try a valid symbol or a specific company name for relevant resultsSign inMailFinance HomeWatchlistsMy PortfolioScreenersPremiumMarketsIndustriesPersonal FinanceVideosNewsTechU.S. Markets closedS&P 5002,978.76-137.63(-4.42%)Dow 3025,766.64-1,190.95(-4.42%)Nasdaq8,566.48-414.29(-4.61%)Global Drug Delivery Industry Report 2019: Analysis on Injection Devices - Discussion of Products, Current/Forecast Markets, Competitors, and OpportunitiesPR NewswireJanuary 7, 2020ReblogShareTweetShareDUBLIN, Jan. 7, 2020 /PRNewswire/ -- The "Drug Delivery: Injection Devices" report has been added to ResearchAndMarkets.com's offering.Research and Markets LogoMoreDespite its relative invasiveness and technological maturity, instrument-based injection of pharmaceutical preparations is regarded as one of the most accurate, effective, reliable, and reproducible methods of therapeutic drug and fluid delivery. Combined sales of injection devices (including syringes and vascular access devices, or VADs) were estimated at $4.8bn, with safety needles and syringes accounting for nearly half of sales.Over the forecast period, total sales are expected to increase at a CAGR of 6.1%, with safety syringes experiencing near double-digit growth and standard syringe sales declining at nearly 6%.The largest driver of the injection devices market is legislative changes requiring the use of safety devices to help prevent needlestick injury. Other growth factors include an increase in the number of outpatient infusion procedures involving the use of long-term VAD placement.This analysis includes a discussion of products, current/forecast markets, competitors, and opportunities in the global syringes market (including standard and safety syringes) and VADs market (including short peripheral, midline, PICC, and central venous catheters, as well as implantable ports) for the US, five major EU markets, Japan, and RoW markets for 2018-2023.Report CoverageAn overview of injection drug delivery technology Related product portfolios offered by leading manufacturers Top-selling injection drug delivery devices, as well as emerging products under development In-depth market and competitive analysesKey HighlightsDespite its relative invasiveness and technological maturity, instrument-based injection of pharmaceutical preparations is regarded as one of the most accurate, effective, reliable, and reproducible methods of therapeutic drug and fluid delivery. Combined sales of injection devices (including syringes and vascular access devices, or VADs) were estimated at $4.8bn, with safety needles and syringes accounting for nearly half of sales. Over the forecast period, total sales are expected to increase at a CAGR of 6.1%, with safety syringes experiencing near double-digit growth and standard syringe sales declining at nearly 6%. The largest driver of the injection devices market is legislative changes requiring the use of safety devices to help prevent needlestick injury. Other growth factors include an increase in the number of outpatient infusion procedures involving the use of long-term VAD placement. The two leading competitors in the injection drug delivery devices market, accounting for nearly 70% of sales, are Becton Dickinson and Smiths Medical.Key Topics Covered1. Injection Devices1.1 Overview1.2 Regulations and guidelines1.3 Needlestick prevention1.4 Standard disposable needles and syringes1.4.1 Market analysis1.4.2 Competitive analysis1.5 Safety needles and syringes1.5.1 Market analysis1.5.2 Competitive analysis1.6 Combined market forecast1.7 Bibliography 2. Vascular Access Devices2.1 Short peripheral catheters2.1.1 Products2.1.2 Market analysis2.1.3 Competitive analysis2.2 Midline catheters2.2.1 Products2.2.2 Market analysis2.2.3 Competitive analysis2.3 Peripherally inserted central catheters 2.3.1 Products2.3.2 Market analysis2.3.3 Competitive analysis2.4 Central venous catheters2.4.1 Products2.4.2 Market analysis2.4.3 Competitive analysis2.5 Implantable ports2.5.1 Products2.5.2 Market analysis2.5.3 Competitive analysis2.6 Bibliography 3. Appendix: Company ListingAngioDynamics Becton Dickinson Cardinal Health Smiths Group Teleflex MedicalList of ExhibitsExhibit 1-1: Standard disposable needles and syringes, market forecast ($m), by region, 2018-23Exhibit 1-2: Becton Dickinson, revenues by segment, 2018Exhibit 1-3: Cardinal Health, revenues by segment, 2018Exhibit 1-4: Smiths Group, revenues by segment, 2018Exhibit 1-5: Standard disposable needles and syringes market, share by supplier, 2018Exhibit 1-6: Safety needles and syringes, market forecast ($m), by region, 2018-23Exhibit 1-7: Safety needles and syringes market, share by supplier, 2018Exhibit 1-8: Injection devices, combined market forecast ($m), by product type, 2018-23Exhibit 2-1: Vascular access devices, combined market forecast ($m), 2018-23 Exhibit 2-2: Short peripheral catheters, market forecast, by region ($m), 2018-23Exhibit 2-3: Becton Dickinson, revenues by segment, 2018Exhibit 2-4: Smiths Group, revenues by segment, 2018Exhibit 2-5: Short peripheral catheters market, share by supplier, 2018Exhibit 2-6: Midline catheters, market forecast, by region ($m), 2018-23Exhibit 2-7: AngioDynamics, revenues by segment, 2018Exhibit 2-8: Midline catheters market, share by supplier, 2018Exhibit 2-9: Peripherally inserted central catheters, market forecast, by region ($m), 2018-23Exhibit 2-10: Peripherally inserted central catheters market, share by supplier, 2018Exhibit 2-11: Central venous catheters, market forecast, by region ($m), 2018-23Exhibit 2-12: Teleflex Medical, revenues by segment, 2018 Exhibit 2-13: Central venous catheters market, share by supplier, 2018Exhibit 2-14: Implantable ports, market forecast, by region ($m), 2018-23Exhibit 2-15: Implantable ports market, share by supplier, 2018Story continuesFor more information about this report visit https://www.researchandmarkets.com/r/czhcngResearch and Markets also offers Custom Research services providing focused, comprehensive and tailored research.Media Contact:Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716CisionMoreView original content:http://www.prnewswire.com/news-releases/global-drug-delivery-industry-report-2019-analysis-on-injection-devices---discussion-of-products-currentforecast-markets-competitors-and-opportunities-300982498.htmlSOURCE Research and MarketsReblogShareTweetShareRecently ViewedYour list is empty.What to Read NextBiocontainment expert on coronavirus: There's no need for average people to panic yetYahoo FinanceA drug shortage due to the coronavirus is a 'considerable risk:' Fmr. FDA deputy commissionerYahoo Finance VideoStock market live updates: Dow drops 1190 points amid coronavirus fears, S&P 500 sees fastest correction in historyYahoo FinanceAmid coronavirus, bitcoin has fallen 6% this week to below $8,800Yahoo FinanceEl-Erian: The Fed will cut rates in March, if not beforeYahoo Finance VideoOil’s Worst Week Since 2011 Puts Pressure on OPEC+ to RespondBloomberg'Stuck in no man’s land': A working mom details dealing with her sick child's student loan billYahoo FinanceMost face masks won’t protect you from the coronavirusYahoo FinanceRichard Branson’s Wealth Falls to Earth as Virgin Galactic SputtersBloombergCoronavirus-induced stock selloff means IPO market is 'on holiday': veteran IPO analystYahoo FinanceMarket Watcher: Over six months we will see the markets higher Yahoo Finance VideoFu Yu Corporation Limited Just Released Its Annual Earnings: Here's What Analysts ThinkSimply Wall St.Don’t buy the stock dip yet, says Goldman as it warns coronavirus will wipe out earnings growth this yearMarketWatchStock market live updates: Stock futures climb after historic rout; coronavirus fears persistYahoo FinanceQ4 e-commerce sales are what's 'saving Walmart': AnalystYahoo Finance VideoBeyond Meat beats on Q4 earnings, founder says 'we would be crazy not to invest in growth right now'Yahoo Finance